KR20220151851A - Functional cosmetic composition comprising complex extract from ecklonia cava, sea swallow's nest, kelp and grape as effective ingredient, and manufacturing method thereof - Google Patents
Functional cosmetic composition comprising complex extract from ecklonia cava, sea swallow's nest, kelp and grape as effective ingredient, and manufacturing method thereof Download PDFInfo
- Publication number
- KR20220151851A KR20220151851A KR1020210059110A KR20210059110A KR20220151851A KR 20220151851 A KR20220151851 A KR 20220151851A KR 1020210059110 A KR1020210059110 A KR 1020210059110A KR 20210059110 A KR20210059110 A KR 20210059110A KR 20220151851 A KR20220151851 A KR 20220151851A
- Authority
- KR
- South Korea
- Prior art keywords
- extract
- kelp
- nest
- cosmetic composition
- ecklonia cava
- Prior art date
Links
- 239000000284 extract Substances 0.000 title claims abstract description 91
- 239000000203 mixture Substances 0.000 title claims abstract description 61
- 239000002537 cosmetic Substances 0.000 title claims abstract description 46
- 241000512259 Ascophyllum nodosum Species 0.000 title claims abstract description 40
- 241001512722 Ecklonia cava Species 0.000 title claims abstract description 39
- 238000004519 manufacturing process Methods 0.000 title claims abstract description 15
- 235000009754 Vitis X bourquina Nutrition 0.000 title abstract description 14
- 235000012333 Vitis X labruscana Nutrition 0.000 title abstract description 14
- 235000014787 Vitis vinifera Nutrition 0.000 title abstract description 14
- 240000006365 Vitis vinifera Species 0.000 title abstract 2
- 239000004615 ingredient Substances 0.000 title 1
- 230000003110 anti-inflammatory effect Effects 0.000 claims abstract description 19
- 238000002156 mixing Methods 0.000 claims abstract description 19
- 230000000694 effects Effects 0.000 claims abstract description 14
- 230000037394 skin elasticity Effects 0.000 claims abstract description 12
- 244000000626 Daucus carota Species 0.000 claims description 36
- 235000005770 birds nest Nutrition 0.000 claims description 36
- 235000005765 wild carrot Nutrition 0.000 claims description 36
- 239000002131 composite material Substances 0.000 claims description 29
- 241000219094 Vitaceae Species 0.000 claims description 26
- 235000021021 grapes Nutrition 0.000 claims description 26
- 238000000605 extraction Methods 0.000 claims description 16
- 239000002904 solvent Substances 0.000 claims description 16
- 238000000034 method Methods 0.000 claims description 12
- 239000006071 cream Substances 0.000 claims description 11
- 210000002966 serum Anatomy 0.000 claims description 11
- 230000037303 wrinkles Effects 0.000 claims description 11
- 239000006210 lotion Substances 0.000 claims description 8
- 239000004480 active ingredient Substances 0.000 claims description 7
- 239000000843 powder Substances 0.000 claims description 7
- 239000000686 essence Substances 0.000 claims description 5
- 239000002674 ointment Substances 0.000 claims description 5
- -1 serum Substances 0.000 claims description 5
- 239000007921 spray Substances 0.000 claims description 5
- 229940018973 ecklonia cava extract Drugs 0.000 claims description 3
- 229940038487 grape extract Drugs 0.000 claims description 3
- 238000002137 ultrasound extraction Methods 0.000 claims description 3
- 238000013329 compounding Methods 0.000 claims description 2
- 230000006872 improvement Effects 0.000 abstract description 8
- 230000002401 inhibitory effect Effects 0.000 abstract description 6
- 230000001747 exhibiting effect Effects 0.000 abstract description 4
- 241000203221 Aerodramus fuciphagus Species 0.000 abstract 1
- 230000037331 wrinkle reduction Effects 0.000 abstract 1
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 24
- 238000002360 preparation method Methods 0.000 description 24
- 241000219095 Vitis Species 0.000 description 12
- 210000003491 skin Anatomy 0.000 description 11
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 10
- 230000000052 comparative effect Effects 0.000 description 10
- 238000011156 evaluation Methods 0.000 description 9
- 239000002994 raw material Substances 0.000 description 9
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 8
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 8
- 102000004889 Interleukin-6 Human genes 0.000 description 8
- 108090001005 Interleukin-6 Proteins 0.000 description 8
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 8
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 8
- 238000009472 formulation Methods 0.000 description 8
- 230000003020 moisturizing effect Effects 0.000 description 8
- 210000004027 cell Anatomy 0.000 description 7
- 239000000428 dust Substances 0.000 description 7
- 230000002757 inflammatory effect Effects 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- 238000009210 therapy by ultrasound Methods 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- 241001474374 Blennius Species 0.000 description 6
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 6
- 210000002950 fibroblast Anatomy 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- 238000002835 absorbance Methods 0.000 description 5
- 230000032683 aging Effects 0.000 description 5
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
- 102000011779 Nitric Oxide Synthase Type II Human genes 0.000 description 4
- 108010076864 Nitric Oxide Synthase Type II Proteins 0.000 description 4
- 230000006378 damage Effects 0.000 description 4
- 230000002849 elastaseinhibitory effect Effects 0.000 description 4
- KWIUHFFTVRNATP-UHFFFAOYSA-N glycine betaine Chemical compound C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 239000003960 organic solvent Substances 0.000 description 4
- 239000013641 positive control Substances 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 102000008186 Collagen Human genes 0.000 description 3
- 108010035532 Collagen Proteins 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 230000003078 antioxidant effect Effects 0.000 description 3
- 150000001720 carbohydrates Chemical class 0.000 description 3
- 235000014633 carbohydrates Nutrition 0.000 description 3
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 230000007613 environmental effect Effects 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 229910001385 heavy metal Inorganic materials 0.000 description 3
- 230000001965 increasing effect Effects 0.000 description 3
- 229910052500 inorganic mineral Inorganic materials 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 239000011707 mineral Substances 0.000 description 3
- 235000010755 mineral Nutrition 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 235000015097 nutrients Nutrition 0.000 description 3
- 230000003647 oxidation Effects 0.000 description 3
- 238000007254 oxidation reaction Methods 0.000 description 3
- 229920001339 phlorotannin Polymers 0.000 description 3
- 230000001766 physiological effect Effects 0.000 description 3
- NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Chemical compound [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 description 3
- 230000028327 secretion Effects 0.000 description 3
- 230000001953 sensory effect Effects 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- WMBWREPUVVBILR-WIYYLYMNSA-N (-)-Epigallocatechin-3-o-gallate Chemical compound O([C@@H]1CC2=C(O)C=C(C=C2O[C@@H]1C=1C=C(O)C(O)=C(O)C=1)O)C(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-WIYYLYMNSA-N 0.000 description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 2
- NCZPCONIKBICGS-UHFFFAOYSA-N 3-(2-ethylhexoxy)propane-1,2-diol Chemical compound CCCCC(CC)COCC(O)CO NCZPCONIKBICGS-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 201000004624 Dermatitis Diseases 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- 108010014258 Elastin Proteins 0.000 description 2
- 102000016942 Elastin Human genes 0.000 description 2
- WMBWREPUVVBILR-UHFFFAOYSA-N GCG Natural products C=1C(O)=C(O)C(O)=CC=1C1OC2=CC(O)=CC(O)=C2CC1OC(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-UHFFFAOYSA-N 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- IOVCWXUNBOPUCH-UHFFFAOYSA-M Nitrite anion Chemical compound [O-]N=O IOVCWXUNBOPUCH-UHFFFAOYSA-M 0.000 description 2
- 241000199919 Phaeophyceae Species 0.000 description 2
- QNVSXXGDAPORNA-UHFFFAOYSA-N Resveratrol Natural products OC1=CC=CC(C=CC=2C=C(O)C(O)=CC=2)=C1 QNVSXXGDAPORNA-UHFFFAOYSA-N 0.000 description 2
- 206010040880 Skin irritation Diseases 0.000 description 2
- LUKBXSAWLPMMSZ-OWOJBTEDSA-N Trans-resveratrol Chemical compound C1=CC(O)=CC=C1\C=C\C1=CC(O)=CC(O)=C1 LUKBXSAWLPMMSZ-OWOJBTEDSA-N 0.000 description 2
- 239000000783 alginic acid Substances 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- 229960001126 alginic acid Drugs 0.000 description 2
- 150000004781 alginic acids Chemical class 0.000 description 2
- POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 229960003237 betaine Drugs 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 230000003833 cell viability Effects 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 208000037976 chronic inflammation Diseases 0.000 description 2
- 230000006020 chronic inflammation Effects 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 2
- 229960003957 dexamethasone Drugs 0.000 description 2
- NOPFSRXAKWQILS-UHFFFAOYSA-N docosan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCCCCCO NOPFSRXAKWQILS-UHFFFAOYSA-N 0.000 description 2
- 235000013399 edible fruits Nutrition 0.000 description 2
- 230000002500 effect on skin Effects 0.000 description 2
- 229940030275 epigallocatechin gallate Drugs 0.000 description 2
- 229940100524 ethylhexylglycerin Drugs 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 230000009931 harmful effect Effects 0.000 description 2
- 210000002865 immune cell Anatomy 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 230000028709 inflammatory response Effects 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 231100001083 no cytotoxicity Toxicity 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 239000003495 polar organic solvent Substances 0.000 description 2
- 150000008442 polyphenolic compounds Chemical class 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 150000004804 polysaccharides Chemical class 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 239000008213 purified water Substances 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 235000021283 resveratrol Nutrition 0.000 description 2
- 229940016667 resveratrol Drugs 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 230000036556 skin irritation Effects 0.000 description 2
- 231100000475 skin irritation Toxicity 0.000 description 2
- LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Chemical compound [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
- DBTMGCOVALSLOR-DEVYUCJPSA-N (2s,3r,4s,5r,6r)-4-[(2s,3r,4s,5r,6r)-3,5-dihydroxy-6-(hydroxymethyl)-4-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-6-(hydroxymethyl)oxane-2,3,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](CO)O[C@H](O)[C@@H]2O)O)O[C@H](CO)[C@H]1O DBTMGCOVALSLOR-DEVYUCJPSA-N 0.000 description 1
- JPFCOVZKLAXXOE-XBNSMERZSA-N (3r)-2-(3,5-dihydroxy-4-methoxyphenyl)-8-[(2r,3r,4r)-3,5,7-trihydroxy-2-(4-hydroxyphenyl)-3,4-dihydro-2h-chromen-4-yl]-3,4-dihydro-2h-chromene-3,5,7-triol Chemical compound C1=C(O)C(OC)=C(O)C=C1C1[C@H](O)CC(C(O)=CC(O)=C2[C@H]3C4=C(O)C=C(O)C=C4O[C@@H]([C@@H]3O)C=3C=CC(O)=CC=3)=C2O1 JPFCOVZKLAXXOE-XBNSMERZSA-N 0.000 description 1
- 229940015975 1,2-hexanediol Drugs 0.000 description 1
- 229940058015 1,3-butylene glycol Drugs 0.000 description 1
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 1
- QCDWFXQBSFUVSP-UHFFFAOYSA-N 2-phenoxyethanol Chemical compound OCCOC1=CC=CC=C1 QCDWFXQBSFUVSP-UHFFFAOYSA-N 0.000 description 1
- AZKSAVLVSZKNRD-UHFFFAOYSA-M 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide Chemical compound [Br-].S1C(C)=C(C)N=C1[N+]1=NC(C=2C=CC=CC=2)=NN1C1=CC=CC=C1 AZKSAVLVSZKNRD-UHFFFAOYSA-M 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 description 1
- 241000195493 Cryptophyta Species 0.000 description 1
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 description 1
- SNPLKNRPJHDVJA-ZETCQYMHSA-N D-panthenol Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCCO SNPLKNRPJHDVJA-ZETCQYMHSA-N 0.000 description 1
- 206010013786 Dry skin Diseases 0.000 description 1
- 238000012286 ELISA Assay Methods 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 206010015150 Erythema Diseases 0.000 description 1
- IMROMDMJAWUWLK-UHFFFAOYSA-N Ethenol Chemical group OC=C IMROMDMJAWUWLK-UHFFFAOYSA-N 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical group CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 1
- 229930064664 L-arginine Natural products 0.000 description 1
- 235000014852 L-arginine Nutrition 0.000 description 1
- 229920001543 Laminarin Polymers 0.000 description 1
- 239000005717 Laminarin Substances 0.000 description 1
- 231100000002 MTT assay Toxicity 0.000 description 1
- 238000000134 MTT assay Methods 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 102000016387 Pancreatic elastase Human genes 0.000 description 1
- 108010067372 Pancreatic elastase Proteins 0.000 description 1
- JPYHHZQJCSQRJY-UHFFFAOYSA-N Phloroglucinol Natural products CCC=CCC=CCC=CCC=CCCCCC(=O)C1=C(O)C=C(O)C=C1O JPYHHZQJCSQRJY-UHFFFAOYSA-N 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 229920001991 Proanthocyanidin Polymers 0.000 description 1
- 102100038280 Prostaglandin G/H synthase 2 Human genes 0.000 description 1
- 108050003267 Prostaglandin G/H synthase 2 Proteins 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 235000019486 Sunflower oil Nutrition 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 239000006096 absorbing agent Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 229960000458 allantoin Drugs 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 239000003899 bactericide agent Substances 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 239000012888 bovine serum Substances 0.000 description 1
- 235000019437 butane-1,3-diol Nutrition 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 229910002091 carbon monoxide Inorganic materials 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000012292 cell migration Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 229940081733 cetearyl alcohol Drugs 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 229960004106 citric acid Drugs 0.000 description 1
- 229960005188 collagen Drugs 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000263 cytotoxicity test Toxicity 0.000 description 1
- ZAKOWWREFLAJOT-UHFFFAOYSA-N d-alpha-Tocopheryl acetate Natural products CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-UHFFFAOYSA-N 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 235000013325 dietary fiber Nutrition 0.000 description 1
- 229960000735 docosanol Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000037336 dry skin Effects 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 229920002549 elastin Polymers 0.000 description 1
- 239000003974 emollient agent Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 231100000321 erythema Toxicity 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 235000013376 functional food Nutrition 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- FOYKKGHVWRFIBD-UHFFFAOYSA-N gamma-tocopherol acetate Natural products CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1 FOYKKGHVWRFIBD-UHFFFAOYSA-N 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229940075529 glyceryl stearate Drugs 0.000 description 1
- 239000004519 grease Substances 0.000 description 1
- FHKSXSQHXQEMOK-UHFFFAOYSA-N hexane-1,2-diol Chemical compound CCCCC(O)CO FHKSXSQHXQEMOK-UHFFFAOYSA-N 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 229940071826 hydroxyethyl cellulose Drugs 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 239000001023 inorganic pigment Substances 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- 238000002386 leaching Methods 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 229940074358 magnesium ascorbate Drugs 0.000 description 1
- AIOKQVJVNPDJKA-ZZMNMWMASA-L magnesium;(2r)-2-[(1s)-1,2-dihydroxyethyl]-4-hydroxy-5-oxo-2h-furan-3-olate Chemical compound [Mg+2].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-] AIOKQVJVNPDJKA-ZZMNMWMASA-L 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 239000004200 microcrystalline wax Substances 0.000 description 1
- 235000019808 microcrystalline wax Nutrition 0.000 description 1
- 229940114937 microcrystalline wax Drugs 0.000 description 1
- 239000012046 mixed solvent Substances 0.000 description 1
- 239000005445 natural material Substances 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- AEIJTFQOBWATKX-UHFFFAOYSA-N octane-1,2-diol Chemical compound CCCCCCC(O)CO AEIJTFQOBWATKX-UHFFFAOYSA-N 0.000 description 1
- 239000012860 organic pigment Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 229940101267 panthenol Drugs 0.000 description 1
- 235000020957 pantothenol Nutrition 0.000 description 1
- 239000011619 pantothenol Substances 0.000 description 1
- 239000013618 particulate matter Substances 0.000 description 1
- 238000005325 percolation Methods 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 229960005323 phenoxyethanol Drugs 0.000 description 1
- QCDYQQDYXPDABM-UHFFFAOYSA-N phloroglucinol Chemical compound OC1=CC(O)=CC(O)=C1 QCDYQQDYXPDABM-UHFFFAOYSA-N 0.000 description 1
- 229960001553 phloroglucinol Drugs 0.000 description 1
- 229930182676 phlorotannins Natural products 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 210000004694 pigment cell Anatomy 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 239000010773 plant oil Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 230000011514 reflex Effects 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000029865 regulation of blood pressure Effects 0.000 description 1
- BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 210000002374 sebum Anatomy 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 230000008054 signal transmission Effects 0.000 description 1
- 210000004927 skin cell Anatomy 0.000 description 1
- 230000037380 skin damage Effects 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 229960001790 sodium citrate Drugs 0.000 description 1
- 235000010288 sodium nitrite Nutrition 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 229940114926 stearate Drugs 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 229960004274 stearic acid Drugs 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000002600 sunflower oil Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- ZTUXEFFFLOVXQE-UHFFFAOYSA-N tetradecanoic acid Chemical compound CCCCCCCCCCCCCC(O)=O.CCCCCCCCCCCCCC(O)=O ZTUXEFFFLOVXQE-UHFFFAOYSA-N 0.000 description 1
- 229940098465 tincture Drugs 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9706—Algae
- A61K8/9711—Phaeophycota or Phaeophyta [brown algae], e.g. Fucus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/98—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution of animal origin
- A61K8/987—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution of animal origin of species other than mammals or birds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/59—Mixtures
- A61K2800/592—Mixtures of compounds complementing their respective functions
- A61K2800/5922—At least two compounds being classified in the same subclass of A61K8/18
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/70—Biological properties of the composition as a whole
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Birds (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Botany (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Dermatology (AREA)
- Zoology (AREA)
- Cosmetics (AREA)
Abstract
Description
본 발명은 감태, 바다제비집, 다시마 및 포도의 복합 추출물을 포함하는 기능성 화장료 조성물에 관한 것으로, 보다 구체적으로는 미세먼지로 인한 피부 염증 개선에 도움을 줄 수 있는 기능성 화장료 조성물에 관한 것이다. The present invention relates to a functional cosmetic composition comprising complex extracts of Ecklonia cava, bird's nest, kelp and grapes, and more specifically, to a functional cosmetic composition that can help improve skin inflammation caused by fine dust.
대기 중 떠다니는 입자상 물질을 먼지라 칭하며 그 중 육안으로 식별이 불가능한 크기의 입자를 미세먼지라 칭한다. 미세먼지의 입경이 작을수록 인체 및 환경에 미치는 영향이 더 크고 유해하다. Particulate matter floating in the air is called dust, and among them, particles of a size that cannot be discerned with the naked eye are called fine dust. The smaller the particle size of the fine dust, the greater the harmful effect on the human body and the environment.
중금속 등 각종 화학물질을 내포하는 초미세먼지는 피부의 대사 흐름을 약화시켜 피지에 대한 조절 기능을 떨어뜨리고 건조증과 가려움증, 피부 트러블을 유발시킨다. 미세먼지에 내포된 중금속과 환경 호르몬 등의 유해물질을 세포의 염증성 사이토카인 분비를 촉진하고 백혈구 수를 증가시켜 알레르기 반응을 유도할 수 있다.Ultrafine dust containing various chemicals such as heavy metals weakens the metabolic flow of the skin, lowers the sebum control function, and causes dryness, itching, and skin troubles. Harmful substances such as heavy metals and environmental hormones contained in fine dust can induce allergic reactions by promoting the secretion of inflammatory cytokines in cells and increasing the number of white blood cells.
또한, 미세먼지가 피부로 흡수되면 색소 세포를 자극하여 주름, 검버섯을 생성하고, 몸속으로 흡수되면 활성산소를 만들고 이것이 피부 내에 있는 콜라겐을 파손해 피부의 탄력을 떨어뜨리고 결과적으로 외인성 노화를 유발시킬 수 있다. In addition, when fine dust is absorbed into the skin, it stimulates pigment cells to create wrinkles and age spots, and when absorbed into the body, it creates active oxygen, which damages collagen in the skin and reduces skin elasticity, resulting in extrinsic aging. can
외인성 노화는 고령화에 따라 나타나는 자연 노화와 달리 외부 환경에 의해 나타나는 것으로, 현재 업계에서는 자외선,산화,건조 등과 같은 환경적 요인을 제어하여 노화를 억제하기 위한 연구가 다수를 이루고 있다. Extrinsic aging is caused by the external environment, unlike natural aging that occurs with aging. Currently, many studies are being conducted in the industry to suppress aging by controlling environmental factors such as ultraviolet rays, oxidation, and drying.
이러한 환경적 요인은 주로 진피층에 포함된 콜라겐 단백질, 엘라스틴 단백질 등을 파괴하거나 변성을 일으켜 주름을 유발한다. 특히, 자외선은 피부 세포(섬유아세포)를 산화시키고 엘라스틴의 생성 저하 및 파괴를 일으키는데, 자외선 등에 의해 피부 내에 엘라스틴 분해효소(elastase)가 발현되면 이 효소가 피부 내의 정상적인 엘라스틴을 분해하여 피부 탄력 저하를 가져오게 된다. These environmental factors mainly cause wrinkles by destroying or denaturing collagen proteins, elastin proteins, etc. contained in the dermal layer. In particular, ultraviolet rays oxidize skin cells (fibroblasts) and cause reduction and destruction of elastin production. will bring
NO는 생체 내에서 혈압조절, 혈소판응집, 신호전달 등 다양한 작용을 하는 것으로 알려져 있다. 전염증성 사이토카인(pro-inflammatory cytokine)이나 LPS는 면역세포에 작용하여 L-아르기닌으로부터 유도성 산화질소 합성효소(inducible nitric oxide synthase, iNOS)의 작용에 의해 NO의 생성을 증가시킨다. 과도한 NO의 생성은 만성 염증과 관련이 있는 것으로 알려짐에 따라 iNOS 활성 조절을 통하여 만성 염증을 조절하기 위한 선택적 NO 생합성 억제제 개발에 많은 연구가 이루어지고 있다 (Sharma et al., 2007; Korhonen et al., 2005).NO is known to have various functions such as blood pressure regulation, platelet aggregation, and signal transmission in vivo. A pro-inflammatory cytokine or LPS acts on immune cells to increase the production of NO by the action of inducible nitric oxide synthase (iNOS) from L-arginine. As excessive NO production is known to be related to chronic inflammation, many studies are being conducted on the development of selective NO biosynthesis inhibitors to control chronic inflammation through the regulation of iNOS activity (Sharma et al., 2007; Korhonen et al. , 2005).
한편, 화학성분이 다량 포함된 화장품의 사용으로 인한 부작용과 피부 자극, 손상에 대한 소비자의 관심이 높아지면서 각종 식물 등의 천연 재료를 이용하여 화장품을 개발하려는 시도가 증가하고 있다. 이를 위해 염증 완화, 산화 방지나 피부 탄력 증진 등 각종 기능성을 보유하면서도 인체에 안전하게 사용할 수 있는 천연 물질의 탐색이 요구된다. 과일이나 조류는 생리 활성에 유용한 여러 기능성 물질을 포함하면서도, 세포 독성이 낮아 이러한 요구에 부합할 수 있는 원료 후보일 수 있다. On the other hand, as consumers' interest in side effects, skin irritation, and damage caused by the use of cosmetics containing a large amount of chemical components increases, attempts to develop cosmetics using natural materials such as various plants are increasing. To this end, it is required to search for natural substances that can be safely used in the human body while maintaining various functions such as relieving inflammation, preventing oxidation, or enhancing skin elasticity. Fruits or algae may be raw material candidates that can meet these requirements because they contain various functional substances useful for physiological activity, but have low cytotoxicity.
본 발명의 목적은 NO 생성을 억제하여 항염증 효능을 나타내는 화장료 조성물을 제공하기 위한 것이다. An object of the present invention is to provide a cosmetic composition exhibiting anti-inflammatory efficacy by inhibiting NO production.
본 발명의 다른 목적은 피부 탄력 또는 주름 개선 효능을 나타내는 화장료 조성물을 제공하기 위한 것이다.Another object of the present invention is to provide a cosmetic composition exhibiting skin elasticity or wrinkle improvement efficacy.
본 발명의 다른 목적은 세포 독성이 없고, 피부 자극이 적은 화장료 조성물을 제공하기 위한 것이다. Another object of the present invention is to provide a cosmetic composition with no cytotoxicity and less skin irritation.
본 발명의 다른 목적은 상기 화장료 조성물의 제조방법을 제공하는 것이다. Another object of the present invention is to provide a method for preparing the cosmetic composition.
본 발명의 일 측면에 따르면, 감태, 바다제비집, 다시마 및 포도의 복합 추출물을 유효성분으로 함유하는, 항염증 효능을 갖는 화장료 조성물을 제시할 수 있다.According to one aspect of the present invention, it is possible to provide a cosmetic composition having an anti-inflammatory effect, containing complex extracts of Ecklonia cava, bird's nest, kelp, and grapes as active ingredients.
상기 화장료 조성물은 피부 탄력 또는 주름 개선 효능을 더 보유한다.The cosmetic composition further has an effect of improving skin elasticity or wrinkles.
상기 복합 추출물 중 각 원료 추출물의 배합비는 감태, 바다제비집, 다시마 및 포도 순으로 3~5: 3~5: 1: 0.5~2 일 수 있다The compounding ratio of each raw material extract in the composite extract may be 3 to 5: 3 to 5: 1: 0.5 to 2 in the order of Ecklonia cava, bird's nest, kelp and grapes.
상기 복합 추출물은 화장료 조성물의 총 중량에 대하여 0.1 중량% 내지 30 중량% 함유될 수 있다. The composite extract may be contained in an amount of 0.1% to 30% by weight based on the total weight of the cosmetic composition.
상기 화장료 조성물은 이에 한정되는 것은 아니지만, 화장수, 세럼, 에센스, 로션, 크림, 파우더, 파운데이션, 팩, 패치, 마스크 시트, 젤 연고, 분무제 또는 세정제의 제형일 수 있다.The cosmetic composition may be, but is not limited to, formulations of lotion, serum, essence, lotion, cream, powder, foundation, pack, patch, mask sheet, gel ointment, spray or cleanser.
또한, 본 발명의 다른 일 측면에 따르면, 전술한 감태, 바다제비집, 다시마 및 포도의 복합 추출물을 유효성분으로 함유하는, 항염증 효능을 갖는 화장료 조성물의 제조방법을 제시할 수 있다.In addition, according to another aspect of the present invention, a method for preparing a cosmetic composition having an anti-inflammatory effect containing the above-described composite extract of Ecklonia cava, bird's nest, kelp, and grape as an active ingredient can be provided.
상기 방법은 감태 추출물, 바다제비집 추출물, 다시마 추출물 및 포도 추출물을 상기한 배합비로 혼합하거나, 각 재료를 상기한 배합비로 혼합한 후 추출하여 복합 추출물을 제조하는 단계를 포함할 수 있다.The method may include preparing a composite extract by mixing Ecklonia cava extract, bird's nest extract, kelp extract, and grape extract in the above mixing ratio, or mixing each material in the above mixing ratio and then extracting.
상기 추출 방법은 감태, 바다제비집, 다시마 및 포도를 커팅 혹은 분쇄하여 1 내지 15 중량 배수의 용매를 가한 후, 15 내지 25℃의 온도 범위에서 30분 내지 3시간 동안 20~40 kHz의 주파수로 초음파 추출하는 것을 포함할 수 있다. The extraction method involves cutting or pulverizing Ecklonia cava, bird's nest, kelp, and grapes, adding 1 to 15 weight multiples of a solvent, and then ultrasonicating at a frequency of 20 to 40 kHz for 30 minutes to 3 hours at a temperature range of 15 to 25 ° C. This may include extraction.
본 발명의 화장료 조성물의 제조방법은 일반적인 화장료 조제용 조성물에 상기 복합 추출물을 0.1 중량% 내지 30 중량% 되게 첨가한 후 통상적인 방법에 따라 화장수, 세럼, 에센스, 로션, 크림, 파우더, 파운데이션, 팩, 패치, 마스크 시트, 젤 연고, 분무제 또는 세정제 등의 제형으로 제형화하는 단계를 포함할 수 있다.The manufacturing method of the cosmetic composition of the present invention is to add 0.1% to 30% by weight of the complex extract to a general cosmetic preparation composition, and then toner, serum, essence, lotion, cream, powder, foundation, pack according to a conventional method , It may include a step of formulating into a formulation such as a patch, mask sheet, gel ointment, spray or cleanser.
본 발명의 감태, 바다제비집, 다시마 및 포도의 복합 추출물을 유효 성분으로 함유하는 화장료 조성물은 항염증 효능이 우수하며, 피부 탄력 또는 주름 개선 등의 피부개선 효과를 더 보유한다.The cosmetic composition containing the complex extracts of Ecklonia cava, bird's nest, kelp and grapes as an active ingredient has excellent anti-inflammatory effect and further possesses skin improvement effects such as skin elasticity or wrinkle improvement.
본 발명의 화장료 조성물은 감태, 바다제비집, 다시마 및 포도의 복합 추출물을 유효성분으로 함유하며, 항염증 효능을 나타낸다. The cosmetic composition of the present invention contains complex extracts of Ecklonia cava, bird's nest, kelp and grapes as active ingredients, and exhibits anti-inflammatory effects.
감태(Ecklonia cava)는 갈조식물 다시마목 미역과의 해조류로 주로 우리나라 남해안과 제주연안,일본해안에 서식, 분포하고 있다. 전복,소라 등의 먹이가 되며 알긴산이나 요오드칼륨을 만드는 주요 원료로 사용되고 있다. Ecklonia cava is a seaweed belonging to the seaweed family of brown algae, kelp, and is mainly inhabited and distributed in the southern coast of Korea, the coast of Jeju, and the coast of Japan. It feeds on abalone and conch, and is used as a major raw material for making alginic acid and potassium iodide.
감태는 최근 해양 생물자원의 활발한 연구를 통해 그 다양한 생리활성이 밝혀지면서 기능성 소재로서 부각되고 있다. 감태 및 곰피에서 여러 플로로탄닌의 존재가 분리, 보고되었는데, 플로로탄닌은 플로로글루시놀을 기본 구성단위로 하는 폴리페놀 화합물이다. 감태와 같은 해조류의 플로로탄닌은 혈전생성 저해활성,항산화활성,심혈관 보호효과 등을 갖는 것으로 보고되었다. Ecklonia cava has recently emerged as a functional material as its various physiological activities have been revealed through active research on marine biological resources. The existence of several phlorotannins has been isolated and reported in Ecklonia cava and Gompi. Phlorotannin is a polyphenolic compound with phloroglucinol as a basic unit. Phlorotannin of seaweeds such as Ecklonia cava has been reported to have thrombogenesis inhibitory activity, antioxidant activity, and cardiovascular protective effect.
바다제비 집(sea swallow's nest)은 바다제비(금사연)가 해초와 생선뼈 등을 모아 타액을 섞어 만드는데, 아미노산, 당, 비타민, 미네랄 등의 영양성분과 교질 단백질이 풍부하고 강장효과가 크다고 알려져 있다.The sea swallow's nest is made by mixing seaweed and fish bones and saliva, and is known to be rich in nutrients such as amino acids, sugars, vitamins and minerals, and colloidal protein, and have a great tonic effect. .
제비의 입에서 나오는 점액질에 의해 해초 등이 젤라틴처럼 교질로 바뀌고,이것이 모아져 굳어진 것이 바로 제비집이다. 바다제비집의 뮤신 성분은 17종의 아미노산으로 구성되어 있다. The slime that comes out of the swallow's mouth turns seaweed into a gelatin-like colloid, which is collected and hardened into a swallow's nest. The mucin component of the bird's nest is composed of 17 amino acids.
다시마는 갈조 식물에 속하는 2-3년생의 해조류로서 탄수화물과 미네랄 성분이 풍부하다. 수분 16%, 단백질 7%, 지방질 1.5%, 탄수화물 49%, 무기질 26.5%를 함유하며, 탄수화물 중 5-10%는 섬유소인데 나머지는 알긴산을 주체로 한 라미나린,푸코이딘 등의 다당류이다. 이들 수용성 다당류는 식이섬유로서 정장작용, 중금속 배출 및 콜레스테롤의 혈관 침착 방지, 노화 방지 등의 효능을 지닌다. Kelp is a 2-3 year old seaweed belonging to the brown algae family and is rich in carbohydrates and minerals. It contains 16% of moisture, 7% of protein, 1.5% of fat, 49% of carbohydrates, and 26.5% of minerals, and 5-10% of carbohydrates are cellulose, and the rest are polysaccharides such as laminarin and fucoidin based on alginic acid. These water-soluble polysaccharides, as dietary fibers, have effects such as intestinal regulation, discharge of heavy metals, prevention of cholesterol deposition in blood vessels, and anti-aging.
포도는 포도당과 과당이 많고,칼륨과 철분이 풍부하며 비타민도 고루 함유된 과일이다. 포도씨 속에는 비타민 E보다 40배나 많은 항산화 물질이 함유되어 있다. 포도씨 속에 존재하는 떫은 맛 성분인 프로안토시아니딘과 포도 껍질에 있는 레스베라트롤은 폴리페놀의 일종인데, 레스베라트롤은 항암 및 항산화 활성, 혈청 콜레스테롤을 낮춰주는 역할을 하는 것으로 알려져 있다. Grapes are a fruit that is high in glucose and fructose, rich in potassium and iron, and also contains vitamins. Grape seeds contain 40 times more antioxidants than vitamin E. Proanthocyanidin, an astringent component present in grape seeds, and resveratrol in grape skins are a type of polyphenol, and resveratrol is known to have anticancer and antioxidant activities, and to lower serum cholesterol.
본 명세서에서, 용어 "항염증"은 염증 반응의 개선이나 경감, 억제 또는 지연을 포함하는 의미로 사용된다. 이러한 염증 반응은 각종 염증 매개 인자와 면역세포와 관련된 효소(예컨대 iNOS, COX-2 등) 활성화, 염증 매개 물질의 분비(예컨대, NO, TNF-α, IL-6 등의 분비), 체액 침윤, 세포 이동, 조직 파괴 등 일련의 복합적인 생리적 반응을 수반하며, 홍반, 통증, 부종, 발열 등의 증상에 의해 외적으로 나타난다. As used herein, the term “anti-inflammatory” is used to include the amelioration or reduction, inhibition or delay of an inflammatory response. These inflammatory responses include activation of various inflammatory mediators and enzymes related to immune cells (e.g., iNOS, COX-2, etc.), secretion of inflammatory mediators (e.g., secretion of NO, TNF-α, IL-6, etc.), body fluid infiltration, It is accompanied by a series of complex physiological reactions such as cell migration and tissue destruction, and is externally manifested by symptoms such as erythema, pain, edema, and fever.
본 발명의 화장료 조성물은 NO 생성의 억제, TNF-α, IL-6 발현 억제를 통한 항염증 효능 이외에도 엘라스테아제 억제를 통한 피부 탄력 또는 주름 개선 효능을 더 보유한다. The cosmetic composition of the present invention further possesses an anti-inflammatory effect through suppression of NO production, TNF-α, and IL-6 expression, as well as an effect of improving skin elasticity or wrinkles through inhibition of elastase.
본 발명에서 감태, 바다제비집, 다시마 및 포도 추출물은 특별히 제한되지 않지만, 구체적으로 추출액, 상기 추출액을 건조시킨 분말, 상기 추출액을 농축 여과한 농축물 등 다양한 형태로 이용될 수 있다.In the present invention, the extracts of Ecklonia cava, bird's nest, kelp, and grapes are not particularly limited, but may be specifically used in various forms, such as an extract, a powder obtained by drying the extract, and a concentrate obtained by concentrating and filtering the extract.
상기 추출액은 예를 들어, 알코올, 정제수, 오일 등을 침출 용매로 포함하는 틴크, 농축물, 엑기스, 유동 엑기스 등의 형태일 수 있다. The extract may be in the form of, for example, tincture containing alcohol, purified water, oil, etc. as a leaching solvent, concentrate, extract, fluid extract, and the like.
본 발명에서 감태, 바다제비집, 다시마 및 포도 추출물의 배합 중량비는 순서대로 3~5: 3~5: 1: 0.5~2일 수 있으며, 상기 배합비 범위 내에서 기대하는 바의 기능성을 구현할 수 있다.In the present invention, the blending weight ratio of Ecklonia cava, bird's nest, kelp, and grape extracts may be 3 to 5: 3 to 5: 1: 0.5 to 2 in order, and the desired functionality can be realized within the range of the blending ratio.
일 구체예에서 상기 감태, 바다제비집, 다시마 및 포도 추출물의 배합비는 추출물의 고형물 중량을 기준으로 측정될 수 있다. 이때, 추출물의 고형물 중량은 감태, 바다제비집, 다시마 및 포도의 조각이나 분쇄물 또는 이들의 혼합물에 용매를 가하여 추출한 이후 동결 건조하여 수득된 고형물일 수 있다. 일 구체예에서, 상기 포도는 원물, 껍질 제외한 건조 알맹이, 건조 껍질 또는 이들의 혼합물일 수 있다. In one embodiment, the blending ratio of the Ecklonia cava, bird's nest, kelp, and grape extracts may be measured based on the solid weight of the extract. At this time, the solid weight of the extract may be a solid obtained by freeze-drying after extracting by adding a solvent to pieces or pulverized materials of Ecklonia cava, bird's nest, kelp, and grapes, or a mixture thereof. In one embodiment, the grapes may be raw, dry kernels excluding skins, dry skins, or a mixture thereof.
다른 구체예에서 상기 감태, 바다제비집, 다시마 및 포도 추출물의 배합비는 원료의 중량을 기준으로 설정될 수 있다. 이때, 원료의 중량은 추출 용매를 가하기 이전의 각 원료 또는 이들의 혼합물에 대한 중량일 수 있다. In another embodiment, the mixing ratio of the Ecklonia cava, bird's nest, kelp, and grape extracts may be set based on the weight of the raw material. In this case, the weight of the raw material may be the weight of each raw material or a mixture thereof before adding the extraction solvent.
상기 복합 추출물은 화장료 조성물의 총 중량에 대하여 0.1 중량% 내지 30 중량%, 구체적으로 1 중량% 내지 25 중량% 함유될 수 있다. 상기 범위 내에서 기대하는 기능성이 발현될 수 있다. The composite extract may be contained in an amount of 0.1% to 30% by weight, specifically 1% to 25% by weight based on the total weight of the cosmetic composition. Expected functionality can be expressed within the above range.
상기 화장료 조성물은 화장수, 세럼, 에센스, 로션, 크림, 파우더, 파운데이션, 팩, 패치, 마스크 시트, 젤 연고, 분무제 및 세정제 중 어느 하나의 제형일 수 있으나, 이에 제한되지 않는다.The cosmetic composition may be any one formulation of lotion, serum, essence, lotion, cream, powder, foundation, pack, patch, mask sheet, gel ointment, spray, and cleanser, but is not limited thereto.
본 발명의 화장료 조성물은 상기 감태, 바다제비집, 다시마 및 포도의 복합 추출물과 함께 화장료 조제용 조성물을 더 포함할 수 있다. The cosmetic composition of the present invention may further include a composition for preparing a cosmetic together with the composite extract of Ecklonia cava, bird's nest, kelp and grape.
화장료 조제용 조성물은 상기 복합 추출물과 함께 목적하는 화장품의 용도와 제형에 따른 화장 효과를 구현하기 위한 것으로, 일반적인 화장료 주제, 부형제 등에 사용되는 성분이라면 특별히 제한되지 않는다. The cosmetic preparation composition is intended to implement a cosmetic effect according to the purpose and formulation of the cosmetic along with the composite extract, and is not particularly limited as long as it is a component used as a general cosmetic subject and excipient.
구체적으로, 상기 화장료 조제용 조성물은 용매, 유지 성분, 보습제, 에몰리엔트제, 계면활성제, 유기 및 무기 안료, 유기 분체, 자외선 흡수제, 방부제, 살균제, 산화방지제, 식물 추출물, pH 조정제, 식물 오일, 색소, 향료 등을 1종 이상 포함할 수 있다. Specifically, the composition for preparing a cosmetic composition includes a solvent, an oil and fat component, a humectant, an emollient, a surfactant, an organic and inorganic pigment, an organic powder, a UV absorber, a preservative, a bactericide, an antioxidant, a plant extract, a pH adjuster, and a plant oil. , It may include one or more kinds of pigments, flavors, and the like.
예를 들면, 상기 화장료 조제용 조성물은 정제수(water), 알코올(alcohol), 글리세린(glycerin), 미리스틱애씨드(myristic acid), 부틸렌글라이콜(butylene glycol), 포타슘하이드록사이드(potassium hydroxide), 폴리에틸렌글리콜(polyethylene glycol), 스테아레이트(sterate), 스테아릭애씨드(steraric acid), 베헤닐알코올(behenyl alcohol), 마이크로크리스탈린왁스(microcrystalline wax), 페녹시에탄올(phenoxyethanol), 에틸헥실글리세린(ethylhexylglycerin), 토코페릴아세테이트(tocopheryl acetate), 1,2-헥산디올(1,2-hexanediol), 카프릴릴글라이콜(caprylyl glycol), 하이드록시에틸렌셀룰로오스(hydroxyethylene cellulose), 하이드록시 에틸 셀룰로오스(hydroxy ethyl cellulose), 잔탄검(xanthan gum), 콜라겐(collagen), 시트르산나트륨(sodium citrate), 시트르산(citrate), 아스코르빈산마그네슘(magnesium ascorbate), 알란토인(allantoin), 판테놀(panthenol), 베타인(betaine), 세테아릴알코올(Cetearyl Alcohol), 해바라기 오일(Sunflower oil), 세테아릴 올리베이트(Cetearyl Olivate), 소르비탄 올리베이트(Sorbitan Olivate), 글리세릴 스테아레이트(Glyceryl Stearate) 및 향료(fragrance) 중 하나 이상 포함할 수 있다.For example, the composition for preparing the cosmetic is purified water (water), alcohol (alcohol), glycerin (glycerin), myristic acid (myristic acid), butylene glycol, potassium hydroxide (potassium hydroxide) , polyethylene glycol, stearate, stearic acid, behenyl alcohol, microcrystalline wax, phenoxyethanol, ethylhexylglycerin ( ethylhexylglycerin), tocopheryl acetate, 1,2-hexanediol, caprylyl glycol, hydroxyethylene cellulose, hydroxy ethyl cellulose ethyl cellulose), xanthan gum, collagen, sodium citrate, citric acid, magnesium ascorbate, allantoin, panthenol, betaine ( betaine, Cetearyl Alcohol, Sunflower oil, Cetearyl Olivate, Sorbitan Olivate, Glyceryl Stearate and fragrance ) may include one or more of
본 발명의 다른 측면은 전술한 감태, 바다제비집, 다시마 및 포도의 복합 추출물을 유효 성분으로 함유하는 기능성 화장료 조성물의 제조방법에 관한 것이다. 상기 방법은 감태, 바다제비집, 다시마 및 포도의 각 추출물을 혼합하거나, 감태, 바다제비집, 다시마 및 포도를 혼합한 후 용매로 추출하여 복합 추출물을 제조하는 것을 포함한다.Another aspect of the present invention relates to a method for producing a functional cosmetic composition containing the above-described composite extract of Ecklonia cava, bird's nest, kelp and grape as an active ingredient. The method includes mixing extracts of Ecklonia cava, bird's nest, kelp, and grapes, or mixing Ecklonia cava, bird's nest, kelp, and grapes, and then extracting with a solvent to prepare a composite extract.
일 구체예에서 감태, 바다제비집, 다시마 및 포도의 복합 추출물을 제조하는 공정에서는 건조된 상태의 감태, 바다제비집, 다시마, 포도를 분쇄 혹은 조각낸 후 용매를 첨가할 수 있다. In one embodiment, in the process of preparing a composite extract of Ecklonia cava, bird's nest, kelp, and grapes, dried Ecklonia cava, bird's nest, kelp, and grapes may be pulverized or shredded, and then a solvent may be added.
상기 용매는 화장료 조제용 추출 용매로 이용가능한 것이라면 특별히 제한되지 않으며, 구체적으로는 물, 유기용매 또는 이들의 혼합물일 수 있다. The solvent is not particularly limited as long as it can be used as an extraction solvent for preparing cosmetics, and specifically may be water, an organic solvent, or a mixture thereof.
상기 유기용매는 에탄올, 프로판올, 메탄올, n-부탄올 등의 탄소수 1 내지 4의 무수 또는 함수 저급 알코올; 아세톤, 1,3-부틸렌글라이콜 등의 극성 유기용매; 에테르, 헥산, 에틸아세테이트 등의 비극성 유기용매; 콩기름, 참기름 등의 식물성 유기용매 등을 포함할 수 있다.The organic solvent may be an anhydrous or hydrous lower alcohol having 1 to 4 carbon atoms such as ethanol, propanol, methanol, and n-butanol; polar organic solvents such as acetone and 1,3-butylene glycol; non-polar organic solvents such as ether, hexane, and ethyl acetate; Vegetable organic solvents such as soybean oil and sesame oil may be included.
상기 유기용매는 1종을 단독으로 사용하거나 2종 이상을 혼합하여 사용할 수 있다. 혼합 용매를 사용하는 경우, 혼합 조성 및 비율은 목적에 따라 적절히 조절할 수 있다.The organic solvent may be used alone or in combination of two or more. In the case of using a mixed solvent, the mixing composition and ratio can be appropriately adjusted according to the purpose.
구체적으로, 본 발명의 복합 추출물은 5~30%의 부틸렌글리콜을 사용하여 초음파 추출하여 제조할 수 있다. Specifically, the complex extract of the present invention can be prepared by ultrasonic extraction using 5 to 30% of butylene glycol.
즉, 각 원료 1 내지 15 중량 배수의 추출 용매를 가하여 15 내지 25℃에서 30분 내지 3시간 동안 20 내지 40 kH의 주파수로 저온 초음파 처리하여 제조될 수 있다. 구체적으로, 상기 초음파 처리는 17~22℃의 온도에서 30분~2시간, 22~38 kHz의 주파수로 수행할 수 있고, 바람직하게는 20℃의 온도에서 1시간, 25~27 kHz의 주파수로 수행할 수 있다. 또한, 상기 초음파 처리는 1~5회 반복 처리할 수 있다. That is, it may be prepared by adding an extraction solvent of 1 to 15 weight multiples of each raw material and subjecting it to low-temperature ultrasonic treatment at a frequency of 20 to 40 kHz for 30 minutes to 3 hours at 15 to 25 ° C. Specifically, the ultrasonic treatment may be performed at a temperature of 17 to 22 ° C. for 30 minutes to 2 hours at a frequency of 22 to 38 kHz, preferably at a temperature of 20 ° C. for 1 hour at a frequency of 25 to 27 kHz. can be done In addition, the ultrasonic treatment may be repeated 1 to 5 times.
상기 조건에서 처리할 경우 추출시간을 단축하면서도 추출 수율을 높이며, 생리 활성을 나타내는 유효 성분의 변성 및 파괴가능성을 최소화시킬 수 있다.When treated under the above conditions, it is possible to shorten the extraction time, increase the extraction yield, and minimize the possibility of denaturation and destruction of active ingredients exhibiting physiological activity.
상기 초음파 추출 방법 이외에도 중탕 추출, 환류냉각 추출, 냉침 추출 및 페르콜레이션(percolation) 등 당업계에 공지된 추출 방법도 사용 가능하다. In addition to the ultrasonic extraction method, extraction methods known in the art such as bath extraction, reflux cooling extraction, cold extraction, and percolation may also be used.
본 발명의 추출물은 상술한 추출 용매에 의해 추출된 추출 물질 뿐만 아니라, 통상적인 정제 과정을 거쳐 추출된 추출 물질도 포함할 수 있다. 예컨대, 일정한 분자량 컷-오프 값을 갖는 한외여과막을 이용한 분리 등 추가적으로 실시된 다양한 정제 방법을 통해 얻어진 활성 분획도 본 발명의 추출물에 포함될 수 있다.The extract of the present invention may include not only an extract material extracted by the above-described extraction solvent, but also an extract material extracted through a conventional purification process. Active fractions obtained through various additional purification methods, such as separation using an ultrafiltration membrane having a certain molecular weight cut-off value, may also be included in the extract of the present invention.
본 발명의 감태, 바다제비집, 다시마 및 포도의 복합추출물은 화장료 조성물 만이 아니라 염증 완화 혹은 피부 탄력이나 주름 개선에 도움이 되는 기능성 식품의 제조에도 사용될 수 있다. 이 경우, 각 원료의 배합비와 추출공정은 앞의 기술과 동일하다. 추출 용매로는 예를 들어, 상기 용매로는 물, 에탄올, 이들의 혼합물을 들 수 있으며 상기 용매의 범위는 당업계의 통상의 지식을 가진자에게 잘 알려져 있다. The composite extract of Ecklonia cava, bird's nest, kelp and grapes of the present invention can be used not only for cosmetic compositions, but also for the preparation of functional foods that help relieve inflammation or improve skin elasticity or wrinkles. In this case, the mixing ratio of each raw material and the extraction process are the same as in the previous technique. Examples of the extraction solvent include water, ethanol, and mixtures thereof, and the range of the solvent is well known to those skilled in the art.
일 구체예에서 복합 추출물의 제조는 감태, 바다제비집, 다시마 및 포도의 추출물을 각각 제조한 후 이들을 3~5: 3~5: 1: 0.5~2의 중량 비율로 혼합하는 것일 수 있다. In one embodiment, the preparation of the composite extract may be to prepare extracts of Ecklonia cava, bird's nest, kelp, and grapes, respectively, and then mix them in a weight ratio of 3 to 5: 3 to 5: 1: 0.5 to 2.
다른 구체예에서 복합 추출물의 제조는 감태, 바다제비집, 다시마 및 포도를 3~5: 3~5: 1: 0.5~2의 중량 비율로 혼합한 후, 추출 용매를 가하여 추출하는 것일 수 있다. In another embodiment, preparation of the complex extract may be performed by mixing Ecklonia cava, bird's nest, kelp, and grapes in a weight ratio of 3 to 5: 3 to 5: 1: 0.5 to 2, and then adding an extraction solvent.
본 발명의 화장료 조성물의 제조 방법은 일반적인 화장료 조제용 조성물에 상기 복합 추출물을 0.1 중량% 내지 40 중량% 첨가한 후, 화장수, 세럼, 에센스, 로션, 크림, 파우더, 파운데이션, 팩, 패치, 마스크 시트, 젤 연고, 분무제 및 세정제 중 어느 하나의 제형으로 제형화하는 단계를 더 포함할 수 있다. The manufacturing method of the cosmetic composition of the present invention is to add 0.1% to 40% by weight of the composite extract to a general cosmetic preparation composition, and then toner, serum, essence, lotion, cream, powder, foundation, pack, patch, mask sheet , The step of formulating into any one formulation of a gel ointment, spray, and detergent may be further included.
상기 제형화 방법은 특별히 제한되지 않으며, 본 발명이 속한 분야에 공지된 다양한 방법을 통해 얻어질 수 있다.The formulation method is not particularly limited, and may be obtained through various methods known in the art to which the present invention pertains.
이하, 본 발명의 바람직한 실시예를 통해 본 발명의 구성 및 작용을 더욱 상세히 설명하기로 한다. 다만, 이는 본 발명의 바람직한 예시로 제시된 것이며 어떠한 이유로도 이에 의해 본 발명이 제한되는 것으로 해석될 수는 없다.Hereinafter, the configuration and operation of the present invention will be described in more detail through preferred embodiments of the present invention. However, this is presented as a preferred example of the present invention and cannot be construed as limiting the present invention by this for any reason.
여기에 기재되지 않은 내용은 본 발명이 속하는 기술 분야에서 숙련된 자이면 충분히 기술적으로 유추할 수 있는 것이므로 그 설명을 생략하기로 한다.Contents not described herein will be omitted because those skilled in the art can sufficiently technically infer them.
실시예 1: 복합 추출물 1(감태, 바다제비집, 다시마 및 포도 중량비 1: 1: 1: 1)의 제조Example 1: Preparation of complex extract 1 (weight ratio of Ecklonia cava, bird's nest, kelp and grape 1: 1: 1: 1)
건조된 감태(제주산)를 물에 헹궈 염을 제거하여 건조하고 약 2cm 크기로 커팅하였다. 바다제비집(말레이시아산)을 수득하고 건조하여 약 2cm 크기로 커팅하였다. 다시마(제주산)는 물에 헹궈 염을 제거하고 건조시켜 약 2cm 크기로 커팅하였다. 포도는 껍질을 벗긴 알맹이를 건조시킨 것(미국산)을 구매하여 사용하였다. The dried Ecklonia cava (Jeju) was rinsed in water to remove salt, dried, and cut into about 2 cm in size. A bird's nest (made in Malaysia) was obtained, dried, and cut to a size of about 2 cm. Kelp (Jeju) was rinsed in water to remove salt, dried, and cut into about 2 cm in size. Grapes were purchased and used by drying the peeled kernels (made in the United States).
상기와 같이 준비된 감태 100g, 바다제비집 100g, 다시마 100g, 포도 100g 의 혼합물 총 중량에 대하여 10 배수의 30% 부틸렌글리콜을 첨가하고, 20℃의 온도에서 1시간 동안 소니케이터(POWERSONIC 510, 화신테크)를 이용하여 25~27 kHz의 주파수로 초음파 처리를 하고, 85℃의 온도에서 2시간 동안 오븐(ON-22GW, JEIO TECH)에 방치한 후, 추출액을 0.2㎛ 필터로 여과하여 추출물을 제조하였다. 100 g of Ecklonia cava prepared as described above, 100 g of bird's nest, 100 g of kelp, and 100 g of grapes were added with 10 times 30% butylene glycol based on the total weight of the mixture, and a sonicator (POWERSONIC 510, Hwashin) was prepared for 1 hour at a temperature of 20 ° C. TECH) using ultrasonic treatment at a frequency of 25-27 kHz, leaving it in an oven (ON-22GW, JEIO TECH) for 2 hours at a temperature of 85 ° C, and then filtering the extract with a 0.2 μm filter to prepare an extract did
실시예 2: 복합 추출물 2(감태, 바다제비집, 다시마 및 포도 중량비 (2: 2: 1: 1)의 제조Example 2: Preparation of complex extract 2 (Ecklonia cava, bird's nest, kelp and grape weight ratio (2: 2: 1: 1)
실시예 1에서와 같이 준비된 감태 200g, 바다제비집 200g, 다시마 100g, 포도 100g의 혼합물 총 중량에 대하여 10 배수의 30% 부틸렌글리콜을 첨가하고, 20℃의 온도에서 1시간 동안 소니케이터(POWERSONIC 510, 화신테크)를 이용하여 25~27 kHz의 주파수로 초음파 처리를 하고, 85℃의 온도에서 2시간 동안 오븐(ON-22GW, JEIO TECH)에 방치한 후 추출액을 0.2㎛ 필터로 여과하여 추출물을 제조하였다.200 g of Ecklonia cava prepared as in Example 1, 200 g of bird's nest, 100 g of kelp, and 100 g of grapes were added with 10 times 30% butylene glycol based on the total weight of the mixture, and the sonicator (POWERSONIC 510, Hwashin Tech), ultrasonic treatment at a frequency of 25 ~ 27 kHz, and left in an oven (ON-22GW, JEIO TECH) for 2 hours at a temperature of 85 ° C. Then, the extract was filtered through a 0.2 μm filter to obtain an extract. was manufactured.
실시예 3: 복합추출물 3(감태, 바다제비집, 다시마 및 포도 중량비 4: 4: 1: 1)의 제조 Example 3: Preparation of composite extract 3 (weight ratio of Ecklonia cava, bird's nest, kelp and grape 4: 4: 1: 1)
실시예 1에서와 같이 준비된 감태 400g, 바다제비집 400g, 다시마 100g, 포도 100g의 혼합물 총 중량에 대하여 10 배수의 30% 부틸렌글리콜을 첨가하고, 20℃의 온도에서 1시간 동안 소니케이터(POWERSONIC 510, 화신테크)를 이용하여 25~27 kHz의 주파수로 초음파 처리를 하고, 85℃의 온도에서 2시간 동안 오븐(ON-22GW, JEIO TECH)에 방치한 후, 추출액을 0.2㎛ 필터로 여과하여 추출물을 제조하였다.400 g of Ecklonia cava prepared as in Example 1, 400 g of seabird's nest, 100 g of kelp, and 100 g of grapes were added with 10 times 30% butylene glycol based on the total weight of the mixture, and the sonicator (POWERSONIC 510, Hwashin Tech) to ultrasonic treatment at a frequency of 25 to 27 kHz, and left in an oven (ON-22GW, JEIO TECH) for 2 hours at a temperature of 85 ° C. Then, the extract was filtered with a 0.2 μm filter An extract was prepared.
비교예: 각 단일 추출물의 제조Comparative Example: Preparation of each single extract
실시예 1에서와 같이 준비된 감태 100g, 바다제비집 100g, 다시마 100g, 포도 100g을 각각의 중량에 대하여 10 배수의 30% 부틸렌글리콜을 첨가하고, 20℃의 온도에서 1시간 동안 소니케이터(POWERSONIC 510, 화신테크)를 이용하여 25~27 kHz의 주파수로 초음파 처리를 하고, 85℃의 온도에서 2시간 동안 오븐(ON-22GW, JEIO TECH)에 방치한 후, 추출액을 0.2㎛ 필터로 여과하여 각각의 단일 추출물을 제조하였다.100 g of Ecklonia cava prepared as in Example 1, 100 g of sea bird's nest, 100 g of kelp, and 100 g of grapes were added with 10-fold of 30% butylene glycol based on the weight of each, and stirred in a sonicator (POWERSONIC) for 1 hour at a temperature of 20 ° C. 510, Hwashin Tech) to ultrasonic treatment at a frequency of 25 to 27 kHz, and left in an oven (ON-22GW, JEIO TECH) for 2 hours at a temperature of 85 ° C. Then, the extract was filtered with a 0.2 μm filter A single extract of each was prepared.
시험예 1: 항염증 활성 평가Test Example 1: Evaluation of anti-inflammatory activity
실시예 및 비교예의 추출물의 항염 효과를 평가하기 위해 산화질소(NO) 생성 억제 활성을 측정하였다. In order to evaluate the anti-inflammatory effect of the extracts of Examples and Comparative Examples, nitric oxide (NO) production inhibitory activity was measured.
NO의 양은 안정한 산화 산물인 아질산염의 양을 측정함으로써 확인하였다. 구체적으로, RAW 264.7 세포(1x104 cells/웰)를 96-웰 플레이트에서 12-18시간 동안 DMEM(Dulbecco's Modified Eagle's Medium) 배지에서 배양한 후, 무혈청 상태에서 1 ㎍/㎖의 LPS와 추출물을 %(v/v) 농도별로 투여하여 24시간 동안 배양하였고, 세포 배양 상등액 100 ㎕를 새로운 96-웰 플레이트에서 그리스 시약(Sigma-Aldrich Co., St. Louis, MO, USA) 100 ㎕와 혼합한 후, 550 nm에서 흡광도를 측정하였다. 아질산염 농도는 아질산 나트륨 표준 곡선과 비교하여 결정하였다. 양성 대조군으로는 아스코르브산(ascorbic acid) (100 ppm) 을 사용하였다.The amount of NO was confirmed by measuring the amount of nitrite, a stable oxidation product. Specifically, after culturing RAW 264.7 cells (1x10 4 cells/well) in a 96-well plate for 12-18 hours in DMEM (Dulbecco's Modified Eagle's Medium) medium, 1 μg/ml of LPS and extracts were added in a serum-free state. It was administered by % (v / v) concentration and cultured for 24 hours, and 100 μl of cell culture supernatant was mixed with 100 μl of grease reagent (Sigma-Aldrich Co., St. Louis, MO, USA) in a new 96-well plate. Then, absorbance was measured at 550 nm. Nitrite concentration was determined by comparison to a sodium nitrite standard curve. As a positive control, ascorbic acid (100 ppm) was used.
그 결과를 아래 표 1 및 표 2에 나타내었다. The results are shown in Table 1 and Table 2 below.
[표 1][Table 1]
[표 2][Table 2]
상기 표에 나타난 바와 같이, 실시예 3의 복합 추출물은 비교예나 다른 실시예에 비하여 강력한 염증 억제 활성을 보유함을 알 수 있었다. As shown in the table above, it was found that the composite extract of Example 3 possesses a strong anti-inflammatory activity compared to Comparative Examples or other Examples.
시험예 2: 피부 탄력 또는 주름 개선 평가Test Example 2: Evaluation of skin elasticity or wrinkle improvement
피부 탄력 또는 주름 개선 효과를 평가하기 위해 실시예 및 비교예의 추출물의 엘라스타제(elastase) 저해 활성을 측정하였다.In order to evaluate the effect of improving skin elasticity or wrinkles, the elastase inhibitory activity of the extracts of Examples and Comparative Examples was measured.
먼저, 피부 섬유아세포인 HDF-N 세포(5x103 cells/웰)에 0.1% triton X-100이 함유된 0.2M Tris-HCl(pH 8.0)을 20 ㎕ 첨가한 후 초음파 분쇄기로 균질화시켰다. 이를 3,000rpm에서 20분 동안 원심분리하여 얻은 상층액을 엘라스타제 저해 활성 측정을 위한 시료로 사용하였다. 상기 200 ㎍/ml의 시료 60㎕, 0.2M Tris-HCl 완충액 100㎕ 및 각 농도 %(v/v)의 실시예 및 비교예의 추출물을 각각 20 ㎕ 혼합한 후, 50 mM N-STANA 20 ㎕ 를 넣고 37℃에서 배양한 후 405nm에서 흡광도를 측정하였다. 양성 대조군으로는 EGCG(epigallocatechin gallate)(100 ppm)를 사용하였다. 그 결과를 표 3 및 표 4에 나타내었다.First, 20 µl of 0.2M Tris-HCl (pH 8.0) containing 0.1% triton X-100 was added to HDF-N cells (5x10 3 cells/well), which are dermal fibroblasts, and then homogenized using a sonicator. The supernatant obtained by centrifugation at 3,000 rpm for 20 minutes was used as a sample for measuring elastase inhibitory activity. After mixing 60 μl of the 200 μg/ml sample, 100 μl of 0.2M Tris-HCl buffer, and 20 μl of extracts of Examples and Comparative Examples at each concentration % (v/v), 20 μl of 50 mM N-STANA was mixed. After incubation at 37 ° C., absorbance was measured at 405 nm. As a positive control, epigallocatechin gallate (EGCG) (100 ppm) was used. The results are shown in Tables 3 and 4.
[표 3][Table 3]
[표 4][Table 4]
상기 표에 나타난 바와 같이, 실시예의 복합 추출물은 비교예에 비하여 대체적으로 엘라스타제 저해 활성이 우수함을 알 수 있다. As shown in the table above, it can be seen that the composite extracts of Examples are generally superior in elastase inhibitory activity compared to Comparative Examples.
시험예 3: 독성 평가 시험Test Example 3: Toxicity evaluation test
실시예의 복합 추출물을 정상 사람 섬유아세포 (normal human fibroblast) 배양시 첨가하여 MTT assay 방법으로 세포 독성 시험을 수행하였다.The cytotoxicity test was performed by the MTT assay method by adding the composite extracts of the examples during culture of normal human fibroblasts.
구체적으로, 섬유아세포(HS86)를 10% 소혈청을 첨가한 DMEM(Dulbecco's Modified Eagle's Medium) 배지에 1 x 104개 접종하고 하루 동안 5% CO2, 37℃에서 배양 후 추출물 시료를 각각의 농도 %(v/v)로 20 ㎕씩 처리하였다.Specifically, 1 x 10 4 fibroblasts (HS86) were inoculated in DMEM (Dulbecco's Modified Eagle's Medium) medium supplemented with 10% bovine serum, cultured at 5% CO 2 and 37°C for one day, and then extract samples were collected at each concentration. % (v/v) was treated with 20 µl each.
1일간 배양 후 MTT(3-(4,5-dimethylthiazol-2-yl)-2,5- diphenyltetrazolium bromide) 시약을 20 ㎕ 처리하고 4시간 동안 더 배양하였다. 염색결정체를 디메틸설폭시드(dimethy sulfoxide)로 녹여내어 540 nm에서 흡광도를 측정하여 상대 비교하였다. 대조군으로는 추출물 시료를 처리하지 않은 배양액을 사용하였다.After culturing for 1 day, 20 μl of MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) reagent was treated and further incubated for 4 hours. Chromosomes were dissolved in dimethyl sulfoxide, and absorbance was measured at 540 nm for relative comparison. As a control, a culture solution not treated with extract samples was used.
세포생존율(%) = 100 - (각 추출물 시료의 흡광도)/(대조군의 흡광도)*100 의 식을 이용하여 세포의 생존능력을 계산하고, 추출물 시료를 처리하지 않은 대조군의 세포증식율(%)을 100으로 할 때의 상대적인 세포증식효과를 하기 표 5에 나타내었다.Cell viability (%) = 100 - (absorbance of each extract sample) / (absorbance of control group) * 100 Calculate the viability of the cells, and the cell proliferation rate (%) of the control group that is not treated with the extract sample The relative cell proliferation effect when set to 100 is shown in Table 5 below.
[표 5][Table 5]
그 결과, 실시예 1 및 3의 추출물 모두 세포 생존을 저해하지 않아 세포 독성이 없음을 확인하였다. As a result, it was confirmed that the extracts of Examples 1 and 3 did not inhibit cell viability and thus had no cytotoxicity.
시험예 4: 염증인자 발현 억제활성 평가Test Example 4: Evaluation of inflammatory factor expression inhibitory activity
복합추출물의 항염증 활성을 추가적으로 검증하기 위해 정상 사람 섬유아세포 배양시에 이를 첨가하여 염증인자인 TNF-α 및 IL-6의 발현 억제능을 평가하였다. 구체적으로, 섬유아세포(HS86)를 48-웰 플레이트에 4 Х 104 cells/well로 접종 하여 24시간 동안 배양하였다. 이후 배지를 교체하고 LPS를 처리한 후, 실시예 1과 실시예 3의 복합추출물을 각각의 농도 %(v/v)로 20 ㎕ 첨가한 후 48시간 동안 배양하였다. 양성대조군으로는 덱사메타손(dexamethasone)을 동일 농도로 처리하였다. 아무 처리도 하지 않은 배양액과 비교하여, 상기 복합 추출물을 처리한 배양액의 TNF-α 및 IL-6 농도의 상대값을 계산하였다. 상기 TNF-α 및 IL-6의 농도는 ELISA 분석법으로 측정하였다. TNF-α 및 IL-6의 억제율(%)에 대한 결과값을 각각 하기 표 6 및 표 7에 나타내었다.In order to additionally verify the anti-inflammatory activity of the complex extract, it was added to culture of normal human fibroblasts, and the ability to inhibit the expression of TNF-α and IL-6, which are inflammatory factors, was evaluated. Specifically, fibroblasts (HS86) were inoculated in a 48-well plate at 4 Х 10 4 cells/well and cultured for 24 hours. Then, after replacing the medium and treating with LPS, 20 μl of the composite extracts of Examples 1 and 3 were added at each concentration % (v / v), and then cultured for 48 hours. As a positive control group, dexamethasone was treated at the same concentration. Compared to the culture medium without any treatment, the relative values of TNF-α and IL-6 concentrations of the culture medium treated with the composite extract were calculated. The concentrations of TNF-α and IL-6 were measured by ELISA assay. Results for the inhibition rate (%) of TNF-α and IL-6 are shown in Table 6 and Table 7, respectively.
[표 6][Table 6]
[표 7][Table 7]
상기 결과로부터 실시예 1에 비해 실시예 3의 복합 추출물이 염증인자 TNF-α 및 IL-6의 발현을 크게 억제하는 것을 알 수 있다. 특히, 0.5% 이상의 농도에서는 양성대조군인 덱사메타손보다 발현 억제율이 높았다. 이 결과는 시험예 1의 NO 억제 활성 평가의 결과와 맥을 같이 하므로, 실시예 3의 복합 추출물은 항염증 효능이 특히 우수함을 확인할 수 있다.From the above results, it can be seen that the complex extract of Example 3 significantly suppressed the expression of the inflammatory factors TNF-α and IL-6 compared to Example 1. In particular, at a concentration of 0.5% or more, the expression inhibition rate was higher than that of dexamethasone, a positive control group. Since this result is consistent with the results of the NO inhibitory activity evaluation of Test Example 1, it can be confirmed that the composite extract of Example 3 has particularly excellent anti-inflammatory efficacy.
상기한 시험예 1 및 4로부터 실시예 3의 복합 추출물은 NO 생성을 억제하고, 염증인자 TNF-α 및 IL-6의 발현을 현저히 감소시켜 강력한 항염증 효과를 발휘하며, 높은 엘라스타제 저해 활성을 가짐으로써 피부 탄력을 높이고 피부주름을 개선할 수 있음을 확인하였다. From Test Examples 1 and 4, the composite extract of Example 3 inhibits NO production and significantly reduces the expression of inflammatory factors TNF-α and IL-6, exerts a strong anti-inflammatory effect, and exhibits high elastase inhibitory activity. It was confirmed that skin elasticity can be increased and skin wrinkles can be improved by having .
감태, 바다제비집, 다시마, 포도의 단독 추출물과 복합 추출물 간의 항염 활성 비교를 통해 상기 효과는 원료의 최적 혼합비에 따른 상승적 효과에 따른 것임을 알 수 있다. Comparison of the anti-inflammatory activities between single extracts and complex extracts of Ecklonia cava, bird's nest, kelp, and grapes showed that the above effects were due to synergistic effects according to the optimal mixing ratio of raw materials.
따라서, 본 발명의 복합 추출물은 피부 염증을 비롯한 염증성 질환의 예방, 개선 또는 치료를 위한 화장품, 식품 및 의약품 등에 널리 활용될 수 있다.Therefore, the composite extract of the present invention can be widely used in cosmetics, foods, and pharmaceuticals for the prevention, improvement, or treatment of inflammatory diseases including skin inflammation.
하기 제조예는 오로지 본 발명사상의 구현을 예시하기 위한 것으로서 본 발명의 범위가 이에 의해 제한되는 것으로 해석되어서는 아니될 것이다. The following preparation examples are only intended to illustrate the implementation of the idea of the present invention and should not be construed as limiting the scope of the present invention thereby.
제조예 1: 복합추출물을 포함하는 크림 제형의 제조Preparation Example 1: Preparation of a cream formulation containing complex extracts
실시예 3의 복합 추출물(복합물)을 포함하는 보습 크림을 하기 표 8에 나타낸 조성 및 조성비(중량 기준)에 따라 통상적인 방법으로 제조하였다.A moisturizing cream containing the complex extract (complex) of Example 3 was prepared in a conventional manner according to the composition and composition ratio (weight basis) shown in Table 8 below.
[표 8][Table 8]
제조예 2: 복합추출물을 포함하는 세럼 제형의 제조Preparation Example 2: Preparation of Serum Formulation Containing Composite Extract
실시예 3의 복합추출물(복합물)을 각각 포함하는 영양 세럼을 하기 표 9에 나타낸 조성 및 조성비(중량 기준)에 따라 통상적인 방법으로 제조하였다.Nutrient serums each containing the complex extract (complex) of Example 3 were prepared in a conventional manner according to the compositions and composition ratios (by weight) shown in Table 9 below.
[표 9][Table 9]
비교제조예 1Comparative Preparation Example 1
표 8의 복합물로 실시예 1의 복합추출물을 사용한 것을 제외하고 제조예 1과 동일하게 보습 크림을 제조하였다. A moisturizing cream was prepared in the same manner as in Preparation Example 1, except that the composite extract of Example 1 was used as the composite of Table 8.
비교제조예 2Comparative Preparation Example 2
표 9의 복합물로 실시예 1의 복합추출물을 사용한 것을 제외하고 제조예 2와 동일하게 영양 세럼을 제조하였다. A nutritional serum was prepared in the same manner as in Preparation Example 2, except that the composite extract of Example 1 was used as the composite of Table 9.
보습감 및 피부상태 개선 효능 평가Evaluation of moisturizing effect and improvement of skin condition
본 발명의 복합추출물을 포함하는 화장료 조성물의 보습감 및 피부상태 개선 효과를 평가하기 위하여 상기 제조예에서 제조한 보습 크림 및 영양 세럼에 대하여 관능평가를 실시하였다.In order to evaluate the effect of improving the moisturizing feeling and skin condition of the cosmetic composition containing the complex extract of the present invention, sensory evaluation was performed on the moisturizing cream and nutrient serum prepared in Preparation Example.
25~35세의 여성 40명을 두 그룹으로 나누어, 그룹 1은 제조예 1 및 2에 따른 보습 크림 및 영양 세럼을, 그룹 2는 비교제조예 1 및 2에 따른 보습 크림 및 영양 세럼을 1일 1회 6주간 지속적으로 사용하게 하였다. 관능평가는 피부 도포 후 느껴지는 보습감, 피부 개선(피부 탄력 및 피부주름 개선) 효과에 대하여 매우 우수(5점), 우수(4점), 보통(3점), 나쁨(2점), 매우 나쁨(1점)의 기준으로 수행하였고, 그 결과를 하기 표 10 및 11에 각각 나타내었다.40 women between the ages of 25 and 35 were divided into two groups, group 1 received moisturizing cream and nourishing serum according to Preparation Examples 1 and 2, and group 2 received moisturizing cream and nourishing serum according to Comparative Preparation Examples 1 and 2 for 1 day. It was continuously used for 6 weeks at a time. Sensory evaluation was very good (5 points), good (4 points), average (3 points), bad (2 points), very bad ( 1 point), and the results are shown in Tables 10 and 11, respectively.
[표 10][Table 10]
[표 11][Table 11]
상기 표 10 및 11에 나타낸 바와 같이, 비교제조예 1 및 2에 비해 제조예 1 및 2의 보습감, 피부상태 개선 효과에 대한 관능평가 점수가 현저히 높으므로 실시예 3의 복합추출물은 실제 화장품 적용시에도 기능성을 유지하여 선호도가 높다는 것이 보여진다. As shown in Tables 10 and 11, compared to Comparative Preparation Examples 1 and 2, the sensory evaluation score for the moisturizing feeling and skin condition improvement effect of Preparation Examples 1 and 2 was significantly higher, so the composite extract of Example 3 was applied to actual cosmetics. It is shown that the preference is high by maintaining the functionality even in the
이상 본 발명의 실시예를 설명하였으나, 본 발명은 상기 실시예에 한정되는 것이 아니라 서로 다른 다양한 형태로 구현될 수 있으며, 본 발명이 속하는 기술 분야에서 통상의 지식을 가진 자는 본 발명의 기술적 사상이나 필수적인 특징을 변경하지 않고서 다른 구체적인 형태로 실시될 수 있다는 것을 이해할 수 있을 것이다. 그러므로 이상에서 기술한 실시예들은 모든 면에서 예시적인 것이며 한정적이 아닌 것으로 이해해야 한다. Although the embodiments of the present invention have been described above, the present invention is not limited to the above embodiments and may be implemented in various different forms, and those skilled in the art to which the present invention belongs can understand the technical spirit or It will be appreciated that it may be embodied in other specific forms without changing its essential features. Therefore, it should be understood that the embodiments described above are illustrative in all respects and not restrictive.
Claims (7)
A functional cosmetic composition containing complex extracts of Ecklonia cava, bird's nest, kelp and grapes as active ingredients and having anti-inflammatory effects.
The functional cosmetic composition according to claim 1, wherein the composition further has an effect of improving skin elasticity or skin wrinkles.
The functional cosmetic composition according to claim 1 or 2, wherein the compounding ratio of Ecklonia cava extract, bird's nest extract, kelp extract and grape extract in the composite extract is 3-5: 3-5: 1: 0.5-2.
The functional cosmetic composition according to claim 3, wherein the mixing ratio is 3-5: 3-5: 1: 1.
The cosmetic composition according to claim 1, in the form of one of lotion, serum, essence, lotion, cream, powder, foundation, pack, patch, mask sheet, gel ointment, spray, and cleanser.
Ecklonia cava extract, bird's nest extract, kelp extract, and grape extract were mixed in a weight ratio of 3-5: 3-5: 1: 0.5-2, or Ecklonia cava, bird's nest, kelp, and grapes were mixed in a weight ratio of 3-5: 3-5: 1 : A method for producing a functional cosmetic composition having anti-inflammatory efficacy, comprising preparing a complex extract by mixing at 0.5 to 2 and extracting by adding a solvent.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020210059110A KR20220151851A (en) | 2021-05-07 | 2021-05-07 | Functional cosmetic composition comprising complex extract from ecklonia cava, sea swallow's nest, kelp and grape as effective ingredient, and manufacturing method thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020210059110A KR20220151851A (en) | 2021-05-07 | 2021-05-07 | Functional cosmetic composition comprising complex extract from ecklonia cava, sea swallow's nest, kelp and grape as effective ingredient, and manufacturing method thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
KR20220151851A true KR20220151851A (en) | 2022-11-15 |
Family
ID=84042084
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020210059110A KR20220151851A (en) | 2021-05-07 | 2021-05-07 | Functional cosmetic composition comprising complex extract from ecklonia cava, sea swallow's nest, kelp and grape as effective ingredient, and manufacturing method thereof |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR20220151851A (en) |
-
2021
- 2021-05-07 KR KR1020210059110A patent/KR20220151851A/en not_active Application Discontinuation
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR102098388B1 (en) | Natural cosmetic formulation with effect for skin homeostasis-maintenance and anti-inflammation | |
KR101988492B1 (en) | Functional cosmetic composition for removing heavy metal and dust containing medicine plant extract and functional cosmetic including the same | |
KR102016027B1 (en) | Cosmetics composition improving skin wrinkle and skin elasticity and cosmetics including the same | |
KR102088728B1 (en) | Cosmetic Composition for Improving Skin Elasticity and Winkles Comprising Plant Complex Extracts as Active Ingredient | |
JP2011088845A (en) | Involucrin expression inhibitor | |
KR102164506B1 (en) | A cosmetic composition for skin regeneration containing a natural extract compound | |
KR102010404B1 (en) | Cosmetics composition having improvement effect of skin reproduction and cosmetics including the same | |
KR102174660B1 (en) | Cosmetic Composition Comprising Fermented Liquor and Powder of Natural Plant and Preparation Methods Thereof | |
KR101954275B1 (en) | Cosmetic compositions containing complex extract of gold kiwi peel and dragon fruit peel, and method manufacturing the same | |
KR102150927B1 (en) | Cosmetic and pharmaceutical compositin comprising sasa quelpaertensis extract and urea | |
KR101584063B1 (en) | Cosmetic composition for improving acne containing desalinized magma seawater and natural complex extract | |
KR102069641B1 (en) | Functional cosmetic composition for anti-dust and anti-inflamatory containing seafood extract and functional cosmetic including the same | |
KR102077069B1 (en) | Composition for anti-oxidation, skin whitening comprising Spartina alterniflora extracts as an active ingredient | |
KR102561258B1 (en) | Composition for controlling sebum and improving pore comprising Jasminum Officinale, Salix Alba (willow) bark and Solanum melogena fruit extract | |
KR102178510B1 (en) | Functional cosmetic composition comprising complex extract of gold kiwi peel and pomegranate peel as effective ingredient, and manufacturing method thereof | |
KR101904501B1 (en) | Cosmetic compositions for improving skin wrinkles or skin elasticity comprising fucosterol | |
KR101960571B1 (en) | Method for preparing apricot extract, the apricot extract prepared therefrom, and skin care or cosmetic composition comprising the apricot extract | |
KR20200057126A (en) | Composition for Regenerating Skin and Enhancing Hair Growth Comprising Apigenin | |
KR20160062401A (en) | Cosmetic composition having Anti-aging and anti-wrinkle effect containing wheat sprout extracts | |
KR20110085543A (en) | Cosmetic composition for alleviating skin inflammation | |
KR102154139B1 (en) | Composition comprising fermentation of sap of painted maple, cacao nibs extract and granat extract | |
KR102337346B1 (en) | Cosmetic composition containing extract of Pinus rigida Mill. for antioxidative or anti-aging | |
KR20220151851A (en) | Functional cosmetic composition comprising complex extract from ecklonia cava, sea swallow's nest, kelp and grape as effective ingredient, and manufacturing method thereof | |
KR20210080181A (en) | Composition for improving skin wrinkles and elasticity containing the extract of Raphanus sativus var. hortensis for. Acanthiformis MAKINO | |
KR101363029B1 (en) | The cosmetic composition for anti-oxident and anti-aging of the skin comprising the Gelidium amansii, Undaria pinnatifida, wheat bud and Monarda horsemint |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
E902 | Notification of reason for refusal | ||
E601 | Decision to refuse application |